Differences between studies mean cross-trial comparisons can be unreliable but the results suggest the Harbinger test may be competitive. Grail used a higher 995 specificity in a key study  minimizing false positives and making comparison to Harbinger challenging but published results at 95 specificity early in development. At 95 specificity Grails sensitivity for stage 1 to 3 cancers ranged from 56 to 90